Top 10 Blue Chip Stocks For 2018

On Wednesday, stocks recovered following the worst day overall since October. The gains were led by the technology sector, which in many cases reversed following their worst day of the year on Tuesday.

However, despite the tech rebound, the blue chips lagged pulling the Dow Jones Industrial Average down less than 0.1%. Nike Inc (NYSE:NKE), a Dow component, fell 7.1%, pulled lower by a lackluster outlook for sales growth.

The technology sector of the S&P 500 rose 0.8%, its biggest gain in three weeks. The Nasdaq, which is tech heavy, rose 0.5%, and the 500 jumped chiefly on gains by technology giants Microsoft Corporation (NASDAQ:MSFT), up 1.3%, Apple Inc. (NASDAQ:AAPL), up 1.1%, and Facebook Inc (NASDAQ:FB), up 1.1%. The PHLX Semiconductor Index (NASDAQ:SOXX) did its part by gaining 1.1%.

Crude oil (WTI) fell 0.4% as data showed that stockpiles of crude hit a new record high. Spot WTI closed at $48.04 per barrel for a fall of 11% so far in March.

At the close, the Dow Jones Industrial Average fell 7 points at 20,661, the S&P 500 rose 4 to 2,348, the Nasdaq gained 28 points to close at 5,822, and the Russell 2000 fell a point to 1,346. The NYSE ‘s primary exchange traded 899 million shares with total volume of 3.5 billion shares, and the Nasdaq crossed 1.8 billion shares. On the Big Board, advancers exceeded decliners by 1.1-to-1, and on the Nasdaq, decliners led by 1.3-to-1. Blocks on the NYSE fell to 6,935 from 7,804 on Tuesday.

Top 10 Blue Chip Stocks For 2018: Teva Pharmaceutical Industries Limited(TEVA)

Advisors’ Opinion:

  • [By Chris Lange]

    Look for Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) second-quarter results on Thursday. The consensus earnings estimate is $1.07 per share, on $5.73 billion in revenue. The shares were last seen at $32.34. The consensus price target is $36.91, and the 52-week trading range is $27.60 to $55.79.

  • [By Dan Caplinger]

    Momenta Pharmaceuticals soared 25% after the biotechnology company won a lawsuit over alleged patent infringement. A Delaware federal district court found that four patents held by Teva Pharmaceutical (NYSE:TEVA) were invalid, opening the door for Momenta to offer its own competing version of a key drug. Momenta CEO Craig Wheeler provided details in his praise of the decision, noting that it “further bolsters our confidence in the potential for us to offer multiple sclerosis patients a more affordable generic version of Copaxone 40 mg following regulatory approval.” Momenta still has to get past some additional hurdles, but investors are hopeful that the path forward is clearer.

  • [By WWW.MONEYSHOW.COM]

    Opioid drug abuse has become a national epidemic; Teva Pharmaceutical Industries Limited (TEVA) has just developed a drug that could potentially deliver pain relief without the scourge of addiction, suggests Jimmy Mengel, editor of The Crow’s Nest.

Top 10 Blue Chip Stocks For 2018: Tenneco Inc.(TEN)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Shares of auto-part makers like Delphi Automotive (DLPH), BorgWarner (BWA), and Tenneco (TEN) are getting killed today, ostensibly due to an article in Automotive News. Wells Fargo’s Richard Kwas and team think Tesla Motors (TSLA) and its Model 3 deserve at least some of the blame:

Top 10 Blue Chip Stocks For 2018: Brookfield Renewable Powerr Fund(BEP)

Advisors’ Opinion:

  • [By Federico Zaldua]

    I expect the Brookfield Group of Companies, which is composed of no fewer than 15 publicly traded entities, to be very active acquisitive in the near-term future. Here I focus my attention on three members of the Brookfield Group that are going to be the most active with M&A. While Brookfield Asset Management (BAM) will concentrate its M&A efforts into all geographies and all asset classes, Brookfield Renewable Energy Partners (BEP) and Brookfield Infrastructure Partners (BIP) will concentrate on their respective industries. Let’s see whether you should go long on any of this separate -although related – entities.

    Good Operational Performance

    Brookfield Asset Management, held by Lou Simpson and Ron Baron, counts with a liquidity position of more than $5 billion at the parent and principal subsidiaries along with nearly $10 billion drawable private fund commitments. More importantly, the company has expressed its interest into using this liquidity to make acquisitions. Management clearly stated in its letter to shareholders:

Top 10 Blue Chip Stocks For 2018: Amphenol Corporation(APH)

Advisors’ Opinion:

  • [By Darren Williams] Although the entire cannabis space has quietly taken a hit of their own medicine in recent weeks and gone to sleep, don’t think for one second the entire space isn’t going to light up again soon. That’s just what they do, right? However, knowing who the pretenders are and knowing who the contenders are is really the challenge when it’s comes right down to it.
    First, anyone who claims to be a grower or a seller of cannabis can’t for one second ever make it as a public company right now, or can even legally consider being a public company for that matter, so you can scratch any of those right off your list. At least here in the U.S. anyway, because Canada is already well ahead of the curve having legalized it for medicinal purposes already.
    More importantly, full legalization of marijuana in Canada appears to be on track for July 2018, which will make Canada just the second nation in the world after Uruguay to completely legalize the cultivation, sale and possession of the drug for medical and recreational purposes.
    Regardless, the best time to buy any stocks in a hot growth sector is when either everyone has forgotten about them, or when the overall market landscape has turned bearish, which has yet to happen. However, the former seems to be the case for the cannabis space, despite some very favorable state legislation last Fall.
    For now, as long as you have a license issued by Health Canada, you’re good to go, so there are some stocks trading in Canada already who are well on their way to making some green for investors. Canopy Growth Corporation (TSE: WEED), formerly Tweed Marijuana Inc., is a medical marijuana company based in Smiths Falls, Ontario. Aurora Cannabis Inc. (CVE: ACB), which is engaged in the production and sale of medical cannabis. There’s also Aphria Pharmaceutical Company (TSE: APH), which also is engaged in producing and selling medical marijuana through retail sales and wholesale channels.
    There are many more, but those are just a
  • [By Lee Jackson]

    This is the top pick in the sector and has remained a favorite at RBC for some time.Amphenol Corp. (NYSE: APH) is one of the worlds largest designers, manufacturers and marketers of electrical, electronic and fiber optic connectors, interconnect systems, antennas, sensors and sensor-based products and coaxial and high-speed specialty cable.

Top 10 Blue Chip Stocks For 2018: Yingli Green Energy Holding Company Limited(YGE)

Advisors’ Opinion:

  • [By Monica Gerson]

    Yingli Green Energy Holding Co Ltd (ADR) (NYSE: YGE) is expected to post a quarterly loss at $1.48 per share on revenue of $372.30 million.

    Ameren Corp (NYSE: AEE) is estimated to post its quarterly earnings at $0.38 per share on revenue of $1.51 billion.

  • [By Spencer Israel]

    Axiom Capital Managing Director Gordon Johnson upgraded the entire alternative energy sector from Market Underweight to Market Overweight and upgraded SolarCity Corp (NASDAQ: SCTY) from Sell to Hold and Trina Solar Limited (ADR) (NYSE: TSL), Yingli Green Energy Holding Co Ltd (ADR) (NYSE: YGE) and JA Solar Holdings Co., Ltd. (ADR) (NASDAQ: JASO) from Sell to Buy.

  • [By Wayne Duggan]

    Despite the potentially positive recent developments for solar investors, Johnson remains extremely bearish on solar stocks. Axiom maintains Sell ratings on the following U.S.-listed names:

    JA Solar Holdings Co. Ltd. (ADR) (NASDAQ: JASO) Yingli Green Energy Holding Co Ltd (ADR) (NYSE: YGE) Solaredge Technologies Inc (NASDAQ: SEDG) Canadian Solar Inc. (NASDAQ: CSIQ)

    Related Link: Politics Here And Abroad: Muted Market Volume Amid Comey’s Testimony And UK’s Election
    _______
    Image Credit: Screengrab from “Trump Makes Statement On Paris Accord” By The White House [Public domain], via Wikimedia Commons

Top 10 Blue Chip Stocks For 2018: iShares MSCI All Peru Capped ETF (EPU)

Advisors’ Opinion:

  • [By Todd Shriber, ETF Professor]

    ARGT, the lone exchange traded fund dedicated to Argentine equities, is up 19.6 percent year-to-date. That is good for the second-best showing among Latin America single-country ETFs, trailing only the iShares MSCI Capped Peru Index Fund (NYSE: EPU).

  • [By Andrew Efimoff] Related Some Positive Indexing News For A Frontier Markets ETF Why The Frontier Markets ETF Slumped Last Year Status Quo Decisions Would Bode Well For PAK ETF (Seeking Alpha)
    Related EPU Peru ETF Confronts Politics Commodities Call For The Colombia ETF Graċ¸½a Y Montero May Have Peaked In 2016 (Seeking Alpha) Gainers Pakistan: Global XMSCI Pakistan ETF (NYSE: PAK) is up 5.67 percent after receiving MSCI’s Emerging Markets Index approval. Peru: iShares MSCI All Peru Capped Index Fund(NYSE: EPU) is up 2.15 percent after Kuzynski won Peru’s nail-biting election. Philippines: iShares MSCI Philippines Investable(NYSE: EPHE) is up 2.21 percent after Macquarie Research said President Elect Rodrigo Duterte would lift the Pilipino property market. India: iShares MSCI India ETF (NYSE: INDA) is up 1.96 percent after India’s government relaxed regulation, making it easier for domestic airlines to fly overseas.

    Related Link: Some Positive Indexing News For A Frontier Markets ETF

Top 10 Blue Chip Stocks For 2018: Actinium Pharmaceuticals, Inc.(ATNM)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Actinium Pharmaceuticals Inc (NYSE: ATNM) were down 24 percent to $1.29. Actinium priced 8 million shares at $1.25 per share.

    Shineco Inc (NASDAQ: TYHT) was down, falling around 32 percent to $19.50. On Wednesday, Shineco priced IPO at $4.50 per share.

Top 10 Blue Chip Stocks For 2018: PCM, Inc.(PCMI)

Advisors’ Opinion:

  • [By Lisa Levin]

    PCM Inc (NASDAQ: PCMI) was down, falling around 26 percent to $14.63. PCM reported Q2 adjusted earnings of $0.47 per share on sales of $560.1 million.

Top 10 Blue Chip Stocks For 2018: SPDR S&P Biotech ETF (XBI)

Advisors’ Opinion:

  • [By ]

    After sneaking lower to begin the new trading week, the SPDR S&P Biotech ETF (NYSE:XBI) and the iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) were each approaching important support levels.

  • [By WWW.KIPLINGER.COM]

    Theres been follow-up, too: Valeant Pharmaceuticals Intl Inc (VRX) had to face the Senate in April for aggressively hiking prices on its drugs. Now Mylan NV (MYL) is answering to the government soon after a story showed that EpiPen prices have rocketed 400% since 2008 with no significant improvements to the treatment. This scandal, too, is rocking biotechs including (Link]recommendation SPDR S&P Biotech ETF (XBI).

  • [By ]

    The SPDR S&P Biotech ETF (NYSE:XBI) and the iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) were each approaching important support levels back in mid-November.

Top 10 Blue Chip Stocks For 2018: Orexigen Therapeutics, Inc.(OREX)

Advisors’ Opinion:

  • [By Peter Graham]

    A long term chart shows Arena Pharmaceuticals along with its small capobesitytreatmentpeers EnteroMedics Inc (NASDAQ: ETRM), Orexigen Therapeutics, Inc (NASDAQ: OREX) and VIVUS, Inc (NASDAQ: VVUS) all causing severe weight loss for investor portfolios:

  • [By Cameron Saucier]

    Orexigen Therapeutics (Nasdaq: OREX) is a biopharmaceutical company that aims to treat obesity. The company’s flagship drug, Contrave, is approved by the Food and Drug Administration (FDA) in the United States. The drug regulates appetite, energy use, and the central nervous system. OREX rose 63% last month after it announced a new commercial and distribution agreement with Biologix FZCO. The agreement will cover 10 countries in the Middle East. OREX is currently trading at $3.30 per share and is down 79% as of Jan. 9 year over year (YOY).

  • [By Keith Speights]

    Arena is out of the obesity drug business, but what about Orexigen Therapeutics (NASDAQ:OREX) or VIVUS (NASDAQ:VVUS)? The problem is that they’re both too dependent on their respective obesity drugs, Contrave and Qsymia. Neither of the drugs have performed up to expectations.

Leave a Reply

Your email address will not be published. Required fields are marked *